Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

The tech giant has shipped weight-loss drugs since 2021. 


Amazon Offers Same-Day Delivery of Eli Lilly’s (LLY) Weight-Loss Pill

Owning the entire market is viewed as a safe investing strategy. 


XLV, VHT, IXJ: Invest in the Healthcare Sector with Exchange-Traded Funds

An update from Holley ( ($HLLY) ) is now available. Holley Inc. announced that Executive Vice President, General Counsel and Corporate Secretary Ca...

Holley Announces Executive Vice President and General Counsel Exit

The obesity medication is forecast to be a bestseller.


Eli Lilly (LLY) CEO Says Company Ready to Scale Production of Weight-Loss Pill

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and P...

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and Praxis Precision Medicines (PRAX)

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The phase 1 trial “A Study of LY4060874 in Healthy Participants” ...

Eli Lilly’s LY4060874 Phase 1 Readout: What a Quiet Pipeline Update Means for LLY Investors

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Structure Therapeutics, Inc. Sponsored ADR (GPCR) an...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvation Bio (NUVB) and Eli Lilly & Co (LLY) with bu...

Shares in Danish drugmaking giant Novo Nordisk ($NVO) — already down about 26% since the start of the year — are now facing even more pressure afte...

Wegovy vs. Foundayo: Novo Nordisk’s “Record-Breaking” Run Meets the Eli Lilly (LLY) Challenge

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and Merit Medical Systems (MMSI...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Merit Medical Systems (MMSI)

The regulatory clearance has arrived sooner than expected. 


Eli Lilly Stock (LLY) Surges as FDA Approves Weight-Loss Pill

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Definium Therapeutics (DFTX) and Eli Lilly & Co (LLY...

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Eli Lilly & Co (LLY)

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,280.00. Bansal covers the Healthcare ...

Eli Lilly & Co (LLY) Gets a Buy from Wells Fargo

Analysts have been eager to weigh in on the Financial sector with new ratings on Ally Financial (ALLY) and Houlihan Lokey (HLI). Ally Financial (AL...

Analysts Offer Insights on Financial Companies: Ally Financial (ALLY) and Houlihan Lokey (HLI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Centene (CNC), Eli Lilly & Co (LLY) and Gilead Scien...

Analysts’ Top Healthcare Picks: Centene (CNC), Eli Lilly & Co (LLY)

The latest stock market stories for Tuesday are ready to go in the daily wrap-up.


Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!

The pharma giant is making a big push into China. 


Eli Lilly Stock (LLY) Gets a Boost from Plan to Make Drugs Using AI

Traders can read the latest stock market happenings in our daily wrap-up.


Morning News Wrap-Up: 3/27/26: Today’s Biggest Stock Market Stories

Investors will find the hottest stock market stories for Wednesday in our wrap-up.


Morning News Wrap-Up 3/25/26: Today’s Biggest Stock Market Stories!

Affordability is an issue for consumers. 


Buy Eli Lilly Stock (LLY) as Employers Move to Cover Obesity Drugs, Says Morgan Stanley

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) has completed a Phase 1 study called ...

Lilly Advances Next-Gen Diabetes Drug With Completed Pediatric PK Study

British bank Barclays ($BCS) continues to urge investors to buy Eli Lilly ($LLY) stock as the share price falls. Analyst Emily Field reiterated a B...

Barclays Continues to Pound the Table on Eli Lilly Stock (LLY) as Share Price Falls

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on Ally Financial (ALLY) and StoneX Group (SNEX) with bu...

Analysts Are Bullish on These Financial Stocks: Ally Financial (ALLY), StoneX Group (SNEX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and The Ensign Group (ENSG) wit...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and The Ensign Group (ENSG)

Eli Lilly & Co ( ($LLY) ) has fallen by -8.33%. Read on to learn why. Eli Lilly & Co shares fell 8.33% over the past week as investors weighed


Eli Lilly & Co Slides as Bold Pipeline Tested

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is running a late-stage study of reta...

Eli Lilly’s Retatrutide Trial Signals Next Wave in Obesity Drug Competition

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study A Study to Assess the Use of the Somfit, an Ambulatory ...

Eli Lilly Advances Digital Sleep Tech Study in Early Alzheimer’s Tracking

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alumis Inc. (ALMS), Larimar Therapeutics (LRMR) and ...

Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Larimar Therapeutics (LRMR) and Eli Lilly & Co (LLY)

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Co. (LLY) is preparing a new Phase 2 trial called E...

Eli Lilly Advances EMERALD-3: A New Oral Bet in Ulcerative Colitis

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study, titled “An Adaptive Two-Stage Bioequivalence Study of ...

Eli Lilly Refines Mirikizumab Delivery With New Phase 1 Injection Study

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is launching a Phase 2 trial titled “...

Eli Lilly Targets Crohn’s Disease With New Combo Trial That Could Extend Its IBD Franchise

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study IIBD is a new Eli Lilly master trial that will test several...

Eli Lilly Launches Master IBD Study, Expanding Its Bet on Ulcerative Colitis and Crohn’s Therapies

IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors

The company has a robust drug pipeline. 


Eli Lilly Stock (LLY) Rises. The Pharma Giant Has Reported Some Very Good News

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), Lantheus (LN...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Lantheus (LNTH) and Monte Rosa Therapeutics (GLUE)

Traders will find the top stock market stories for Tuesday in our daily wrap-up.


Morning News Wrap-Up 3/17/26: Today’s Biggest Stock Market Stories!

The company’s weight-loss pill is hotly anticipated. 


Eli Lilly Stock (LLY) Gets a Rare Downgrade. HSBC Sees This Problem Ahead

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,280.00. According to TipRanks, Bansal...

Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

The surge in oil prices due to the U.S.-Iran conflict has sparked fears of stagflation – a combination of stagnation and inflation that describes a...

3 Best Stocks to Buy amid Stagflation Fears, According to Analysts

The company faces little competition in the weight-loss drug space. 


RBC Capital Markets Pounds the Table on Eli Lilly Stock (LLY) as Share Price Falls

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. This early Eli Lilly study, titled “A Phase 1, Multicenter, Paral...

Lilly Advances Eloralintide Study in High-Risk Kidney Patients: What Investors Should Know

Bernstein analyst Courtney Breen maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1,300.00. The company’s shares clos...

Eli Lilly & Co (LLY) Receives a Buy from Bernstein

Jarden analyst Steven Wheen maintained a Buy rating on CSL on March 9 and set a price target of A$270.00. The company’s shares closed yesterday at ...

Jarden Reaffirms Their Buy Rating on CSL (CMXHF)

Eli Lilly ($LLY) has pledged to invest $3 billion in China over the next decade as the U.S. pharmaceutical giant seeks regulatory approval for its ...

The Not So Subtle Reason Why Eli Lilly (LLY) Is Investing $3 Billion in China

Healthcare is diverse sector of the economy. 


Market Cap	$788.86B	P/E Ratio	27.44
52W High	$1,133.95	52W Low	$623.78
Div Yield	692.0%	Payout Ratio	123.2%
EPS Growth 3Y	24.1%	52W Position	64.6%
Overall Score	48	Value Score	40
Quality Score	68	Technical Score	36

EPS Current Est	$34.74	EPS Next Est	$41.9
EPS Growth Est	+20.6%	DPS Growth 3Y	16.7%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LLY	$953.30	0.00%	2.57M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LLY	$953.30	0%	2.57M
3
4
5
6

LLY

LLY

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Eli Lilly and Company Data in Excel

Get Eli Lilly and Company Data in Excel